http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-506091-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 1999-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e64246df21f0926b95fe038458129ed3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08e82ec255f3bef662a34ca8e5d44eef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d07b821a9f0fe627ac2cef1a8fc9038a |
publicationDate | 2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | NZ-506091-A |
titleOfInvention | Circulating insulin-like growth factor-i and prostate cancer risk |
abstract | A method of predicting increased risk of prostate cancer in an individual without prostate cancer. It involves the measuring the concentration of insulin-like growth factor (IGF-I) in a body fluid from an individual. An elevated concentration of IGF above a reference range for IGF indicates an increased risk for prostate cancer in the future. Body fluid used may include blood, plasma, serum and seminal fluid. Additionally, the concentrations of IGF-I and insulin-like growth factor-1 (IGFB-3) are measured. A multivariate adjustment of IGF-I concentration relative to IGFB-3 provides an adjusted IGF-I level. Where such a level is above a reference range for adjusted IGF-I indicates an increased risk for prostate cancer in the future. A multivariate adjustment of the IGF-I concentration relative to the PSA concentration to provides an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for prostate cancer in the future with a poor prognosis. A multivariate adjustment of the IGF-I concentration relative to IGFBP and PSA concentrations to provide an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for severe prostate cancer in the future. IGF-I concentrations are compared to a reference group without prostate cancer to establish a reference level. |
priorityDate | 1998-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 339.